171 results
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
across all scopes of emissions by 2030, and net zero greenhouse gas emissions by 2045, five years earlier than previous targets. By the end of 2022
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
investor event
Progress on Corporate Social Responsibility strategy in Q2
Inclusivity targets implemented across clinical trial; 45% of U.S. trials … % at CER).
Corporate Social Responsibility update at the end of the second quarter 2023
Access to healthcare
Inclusivity targets implemented across
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
, mentorship, internship opportunities, and potential employment once they graduate.
Inclusivity targets implemented across clinical trials with 45% of U.S … barriers.
Building on these insights, Sanofi sets inclusivity targets in line with the demographics of the disease. It also seeks to be inclusive through
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
RNAs for multiple targets including sickle cell disease and other genomic diseases. Under the terms of the agreement, Scribe Therapeutics will receive
6-K
EX-99.3
SNY
Sanofi
5 Jul 23
Current report (foreign)
8:43am
and bacterial targets. Using a powerful internal and external innovation ecosystem, Sanofi’s mRNA Center of Excellence has accelerated the science of mRNA
6-K
EX-99.1
scc7nihqh0v qbzjp
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.3
15w eozpusj8
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
rlkdbz4
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
7q38cg yp8m79jgk5
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
bzfotur0g
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
eiwx imwnv0p8wnon5z
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.2
adx 2xo0ok2oh54u
17 May 22
Current report (foreign)
3:20pm
6-K
EX-99.1
qlkk08dlv12
16 May 22
IFRS net sales reported
1:45pm
6-K
EX-99.1
kv3c8w7l6c4nb5visagv
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.2
7qvv0s
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
oea38
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
imkf3qlpc nyj3ok
31 Mar 22
Current report (foreign)
12:12pm
6-K
EX-99.3
ywbwzysxls6z
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
dof9nr qh7txtksb
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
EX-99.4
ixj0hc6 04z0p19xz9en
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm